ESMO 2024
September 13-17, 2024

As part of scientific exchange, Novartis is providing the most recent abstract(s) accepted by the referenced medical congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Novartis products.
Not all content may be available. Dependent on congress policy, links to the original poster/slide deck may only be available via the congress site where registration may be needed to access.

Content to be used in accordance with local CPO guidelines

List of Presentations

LuMIERE: A Phase 1/2 Study Evaluating Safety, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Patients With Advanced Solid Tumors

Jonathan McConathy*, Yusuf Menda, Jordi Rodon, Ajit H. Goenka, Ryan H. Moy, Sophie Morse, Arnaud Demange, Paola Aimone, Thomas A. Hope

  • Presentation #671P – Poster
    Hall 6 | Saturday, September 14, 2024 | 09:00-17:00 CEST

This presentation will be available once the congress embargo lifts

*Presenting Author
View list of select presentations for this compound